Phase 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done with the 1st Interim Analysis for NDA Approval.

Must Read

TOKUSHIMA, Japan–(BUSINESS WIRE)–150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, Decitabine, Venetoclax combo-regimens) or intensive reinduction (high and intermediate dose of Cytarabine regimens) in the 2nd, 3rd, or 4th salvage of AML and the 1st interim analysis of this study shall be done for NDA approval to the FDA in US soon after confirmation of the superiority of DFP-10917 arm. The endpoint is CR rate for primary and the Overall Survival for secondary. DFP-10917 (Radgocitabine) was granted as Orphan Drug Designation (ODD) by the FDA in US.



Yasuo Matsueda

Vice President for Business Development

Delta-Fly Pharma, Inc.

Head office: Tokushima 771-0116, Japan

Phone: +81-(0)3-6231-1278

E-mail: [email protected]
Home page:


Partnered Events

Latest News

CIMC Raffles secures EPC contracts for Petrobras’ new FPSO hulls

CIMC Raffles, a subsidiary of CIMC Group, has been awarded the engineering, procurement and construction (EPC) contract to supply...

More Articles Like This